Articles tagged with Drug Studies
A clinical trial showed that an extract of Boswellia, a plant used in traditional medicine for centuries, has anti-proliferative effects against breast cancer. The study found a statistically significant reduction in tumor proliferation compared to non-treated patients, suggesting potential anti-cancer activity in humans.
Researchers at Kennedy Krieger and Boston Children's Hospital have discovered a new way to decrease early seizure likelihood among infants with Sturge-Weber Syndrome. Presymptomatic treatment involving anti-seizure medication and low-dose aspirin improves neurologic outcomes.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
A study of nearly 900 patients found that delayed or missed diagnoses contributed to temporary or permanent harm in three-quarters of cases. Improving diagnostic tools and techniques could reduce errors by up to 40%, according to researchers.
A new study found that fentanyl-laced prescription pills are driving a surge in overdose deaths among high school age adolescents in the US. The death rate for this group has increased to 5.2 per 100,000, with Arizona and Colorado experiencing rates double the national average.
Cancer immunotherapy can cause severe colitis due to hyper-activated immune T cells and deleted regulatory T cells. Researchers at Michigan Medicine have identified a new mouse model that develops colitis after treatment with antibodies used for tumor immunotherapy, revealing the mechanism behind this side effect.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
A large-scale German-wide randomized controlled trial found that high-dose therapy with glucocorticoids is not more effective than standard treatment for sudden hearing loss. However, it was associated with a higher risk of side effects. Several hundred thousand people worldwide suffer from sudden hearing loss each year.
Researchers found that higher levels of omega-3 fatty acids in the blood plasma were associated with better lung function and longer survival without needing a lung transplant. This was consistent regardless of smoking history or cardiovascular disease.
A new study found that cytisine significantly increases the chances of successful smoking cessation by more than two-fold compared to placebo. The study also suggests that cytisine may be more effective than nicotine replacement therapy in some cases, making it a promising solution for smokers worldwide.
A recent study found that doxycycline prophylaxis did not prevent bacterial sexually transmitted infections (STIs) among cisgender women, despite being prescribed to 18% of participants. The study also revealed high rates of antibiotic-resistant gonorrhea, which may be due to low adherence and limited treatment options.
A systematic review and meta-analysis of 20 observational studies found a significant association between sedative-hypnotic medication use and an increased risk of fractures. The study estimates that users have a 30% higher risk of fractures compared to non-users, with the highest risk associated with benzodiazepine and z-drug use.
A monoclonal antibody treatment increased food-allergic children and adolescents' tolerance to common foods, reducing allergic reactions. Omalizumab, approved for other indications, is being reviewed for a new indication based on the trial's interim analysis.
A study by the University of Sydney and University of Warwick found large gaps in evidence regarding opioid medicines for cancer pain. Non-opioid medicines, including aspirin, may be as effective as opioids for background cancer pain.
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.
A clinical trial found that an experimental drug, BI 690517, reduced albuminuria in 70% of patients when paired with a standard-care medication. The study also showed that the combination of the two drugs mitigated the risk of hyperkalemia.
A study found that over 13% of cancer drug trials in China used suboptimal control arms, which may lead to biased results and patient harm. The researchers highlight the need for refining trial design to generate optimal clinical evidence.
A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.
A phase 3 trial found that tirzepatide promotes additional weight loss and preserves metabolic health when continued, but discontinuation leads to significant weight regain. Researchers suggest chronic treatment may be necessary for sustained weight loss and improved cardiometabolic risk factors.
A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
A small molecule drug compound has shown promise in treating multiple sclerosis by targeting the glutamate system, reducing MS-like symptoms and repairing damaged myelin. The results come from a CAMH-led pre-clinical study published in Science Advances.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
The TAF/EVG fast-dissolving vaginal insert is being evaluated in a Phase 1 study to determine its safety and user acceptability. The study aims to assess the product's effectiveness as an on-demand HIV prevention method for women, particularly those who do not want or can't use daily PrEP or long-acting products.
Imetelstat, a telomerase inhibitor, successfully treated anaemia in MDS patients for up to one year, reducing the need for red blood cell transfusions. The drug offers a novel mechanism of action for patients with lower-risk MDS who do not respond to standard treatment.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers found that statin therapy reduced mortality and disease risk among people with chronic kidney disease and frailty, regardless of age-related health conditions. The studies provide additional context to the debate about initiating statin use in people at high risk for heart disease.
A Phase 2 clinical trial will study the effectiveness of a monoclonal antibody treatment, TS23, in reducing brain injury and improving outcomes for patients with acute ischemic stroke. The SISTER study aims to provide new hope for treatment and recovery for patients where time and access may have been limited.
Researchers discovered the PanH enzyme, which catalyzes the selective epoxidation of cyclohexenones, a challenging reaction to achieve through chemical synthesis. The study shows that this enzyme can produce a large library of substances with improved and more specific activities in biomedical research.
Researchers at Johns Hopkins Medicine discovered a promising experimental drug combination that reduces the size of peripheral nerve sheath tumors in mice and increases survival rates. The combination blocks glutamine metabolism and purine recycling, producing a better anti-tumor response with less toxicity.
The Lung-MAP trial has demonstrated the potential of public-private partnerships in clinical research, increasing access to new treatment options for patients with lung cancer. The unique partnership between academia, advocacy, federal agencies, and industry has led to a more representative patient group being enrolled in clinical trials.
A new study using smartphone app data found certain medications like triptans, ergots, and anti-emetics to be two to five times more effective than ibuprofen for migraine treatment. Researchers analyzed over 3 million treatment attempts with various medications, including NSAIDs and combination therapies.
A two-year study found that participants who received personalized coaching experienced a modest boost in cognitive testing, measuring a 74% improvement over the non-intervention group. Additionally, improvements were noted between the two groups in measurements of risk factors and quality of life.
Two large studies found that people with ADHD who take medication for a long time and in higher doses are at a higher risk of developing some cardiovascular diseases. The highest rate of discontinuation occurred among 18 to 19-year-olds, highlighting the need for better transition to adult psychiatry services.
A new study will compare two treatment regimens: one using non-opioid medication and another with a low-dose opioid to determine the safest and most effective way to treat pain in adolescents and young adults recovering from common outpatient surgeries. The CARES for Kids study aims to generate evidence-based information on this topic.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers at UCSF and Kaiser Permanente Washington found that participants who received personalized coaching experienced a 74% improvement in cognitive testing compared to non-intervention participants. The study also showed improvements in risk factors and quality of life, with modest but significant increases in cognitive function.
Researchers at University of California - San Francisco find that sense of taste signals brain to slow down eating. Using advanced techniques, they recorded brain activity in awake mice and found PRLH neurons controlled by mouth signals when eating normally, not gut signals as previously thought.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
Researchers found that immunomodulatory drugs used to treat rheumatoid arthritis can reduce the risk of autoimmune thyroid diseases. Patients treated with these drugs had a 46% lower risk of developing an autoimmune thyroid disease compared to those without rheumatoid arthritis.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
Researchers found that three medicines - CGRP inhibitors, amitriptyline, and simvastatin - had a better preventive effect on migraine than traditional beta blockers. This discovery could have significant implications for healthcare costs, as the cheaper alternatives may offer similar treatment effects.
Scientists at Texas Biomedical Research Institute found a promising cancer therapy also effectively reduces TB growth, even for drug-resistant bacteria. The therapy combines MCL-1 and BCL-2 inhibitors with antibiotics to control TB up to 98%.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
A new study suggests that genetic testing for depression could lead to significant cost savings and improved patient outcomes. The test, known as pharmacogenomic testing, can help match patients with medications that are more likely to be effective and cause fewer side effects.
Researchers from Mass General Brigham found that patients experiencing virologic rebound after treatment may remain contagious. The study suggests that individuals shed live virus when experiencing a rebound, implying the potential for transmission after initially recovering from the virus.
A three-year intensive treatment strategy to lower systolic blood pressure below 120mmHg significantly reduced cardiovascular events, including heart attack, stroke, and death, compared to standard treatment. The study found that participants in the intensive group experienced fewer major vascular events and deaths over a two-year period.
A 20% reduction in major adverse cardiovascular events has been observed for patients with obesity but no history of diabetes taking semaglutide. This study marks a significant milestone, demonstrating the cardiovascular benefits of semaglutide beyond its weight loss effects.
Researchers found that people with overweight or obesity who took semaglutide for over 3 years had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease. The study showed significant weight loss and improved cardiovascular outcomes in adults without diabetes.
Researchers found that abelacimab, a Factor XI inhibitor, reduced bleeding compared to rivaroxaban in patients with atrial fibrillation. The study showed significant reduction in hospitalization due to bleeding and almost eliminated gastrointestinal bleeding.
A new study suggests that a PCSK9 inhibitor given every 1-3 months may effectively lower bad cholesterol levels in people with non-genetic hypercholesterolemia. The medication, recaticimab, showed similar effectiveness and safety as other PCSK9 inhibitors when administered less frequently.
A randomized controlled trial suggests that a more liberal approach to red blood cell transfusions for heart attack patients with anemia may benefit outcomes without significant risk. The study found no statistically significant difference between two transfusion strategies, but results suggest a possible benefit of liberal transfusions.
A single dose of zilebesiran safely and effectively lowered systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months. The study found significant reductions in daytime and nighttime systolic blood pressure, as well as low rates of adverse events.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A study found that pregnant women with high blood pressure who received tight blood pressure control immediately after pregnancy had lower blood pressure levels and improved cardiac function compared to those with usual care. This could lead to a reduced risk of cardiovascular disease, including heart attacks and strokes.
A phase 4 clinical trial found that apixaban, an anti-clotting medication, reduced the rate of stroke and blood clots in adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms. The study suggests that these individuals may benefit from receiving an anticoagulant.
A single infusion of CRISPR-based gene-editing therapy significantly reduced LDL cholesterol levels in people with heterozygous familial hypercholesterolemia, a condition that increases heart attack risk. The treatment has shown potential as a long-term or permanent option for high LDL-C control.
The ORBITA-2 trial found that stenting improves symptoms compared to a placebo procedure, providing evidence-based treatment for stable chest pain. The study suggests updating guidelines for stable coronary artery disease and offers patients and medical teams two treatment strategies with similar benefits.
A four-year blood-pressure intervention significantly reduced the risk of developing dementia among adults with high blood pressure, compared to those who received usual care. The study found that lowering systolic blood pressure to less than 130 mm Hg and diastolic blood pressure to less than 80 mm Hg reduced dementia risk.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.